PSMD14 is a novel prognostic marker and therapeutic target in osteosarcoma

Jiabin Lai,Weike Kong,Qiangchang Fu,Zhaochang Jiang,Bohao Sun,Xin Ye,Jing Kong,Shumei Wei,Lifeng Jiang
DOI: https://doi.org/10.1186/s13000-024-01489-y
2024-06-13
Diagnostic Pathology
Abstract:Osteosarcoma is a bone tumor that is characterized by high malignancy and a high mortality rate, and that originates from primitive osteoblastic mesenchymal cells and is most common in rapidly growing long bones. PSMD14, also known as RPN11 or POH1, is a member of the JAMM isopeptidase family, which is able to remove the substrate protein ubiquitination label, thereby regulating the stability and function of the substrate protein. In this study, we explored the expression and potential biological significance of the PSMD14 deubiquitinating enzyme in osteosarcoma.
pathology
What problem does this paper attempt to address?